Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis

Wojtukiewicz, 2019, It is not just the drugs that matter: the nocebo effect, Cancer Metastasis Rev, 38, 315, 10.1007/s10555-019-09800-w Kennedy, 1961, The nocebo reaction, Med World, 95, 203 Enck, 2008, New insights into the placebo and nocebo responses, Neuron, 59, 195, 10.1016/j.neuron.2008.06.030 Evers, 2018, Implications of placebo and nocebo effects for clinical practice: expert consensus, Psychother Psychosom, 87, 204, 10.1159/000490354 Benedetti, 2008, Mechanisms of placebo and placebo-related effects across diseases and treatments, Annu Rev Pharmacol Toxicol, 48, 33, 10.1146/annurev.pharmtox.48.113006.094711 Sertkaya, 2019, Silodosin has nocebo effect on sexual adverse effects: a randomized controlled trial, Eurasian J Med, 51, 277, 10.5152/eurasianjmed.2019.19139 Kleine-Borgmann, 2018, Nocebo effects: neurobiological mechanisms and strategies for prevention and optimizing treatment, Int Rev Neurobiol, 138, 271, 10.1016/bs.irn.2018.02.005 Lozo, 2019, The placebo effect in overactive bladder syndrome, 27 van Leeuwen, 2006, The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms, Eur Urol, 50, 440, 10.1016/j.eururo.2006.05.014 Mangera, 2011, The placebo effect in overactive bladder syndrome, Nat Rev Urol, 8, 495, 10.1038/nrurol.2011.99 Benedetti, 2003, Placebo-induced analgesia: methodology, neurobiology, clinical use, and ethics, Rev Analg, 7, 129, 10.3727/000000003783992955 Andersson, 2017, Drugs for the overactive bladder: are there differences in persistence and compliance?, Transl Androl Urol, 6, 597, 10.21037/tau.2017.03.90 Basra, 2008, A review of adherence to drug therapy in patients with overactive bladder, BJU Int, 102, 774, 10.1111/j.1464-410X.2008.07769.x Higgins, 2011, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 Moher, 2010, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Int J Surg, 8, 336, 10.1016/j.ijsu.2010.02.007 Chancellor, 2000, Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms, Clin Drug Invest, 19, 83, 10.2165/00044011-200019020-00001 Rief, 2009, Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials, Drug Saf, 32, 1041, 10.2165/11316580-000000000-00000 Justice, 1999, Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group, J Acquir Immune Defic Syndr, 21, 126 Brinkhaus, 2008, Who controls the placebo? Introducing a placebo quality checklist for pharmacological trials, Contemp Clin Trials, 29, 149, 10.1016/j.cct.2007.06.005 Rosenthal, 1976 Rief, 2006, Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects, Arch Intern Med, 166, 155, 10.1001/archinte.166.2.155 Papakostas, 2009, Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD, Eur Neuropsychopharmacol, 19, 34, 10.1016/j.euroneuro.2008.08.009 Kirsch, 2019, Placebo effect in the treatment of depression and anxiety, Front Psychiatry, 10, 407, 10.3389/fpsyt.2019.00407 Benedetti, 2005, Neurobiological mechanisms of the placebo effect, J Neurosci, 25, 10390, 10.1523/JNEUROSCI.3458-05.2005 Benedetti, 2007, When words are painful: unraveling the mechanisms of the nocebo effect, Neuroscience, 147, 260, 10.1016/j.neuroscience.2007.02.020 Colloca, 2008, The role of learning in nocebo and placebo effects, Pain, 136, 211, 10.1016/j.pain.2008.02.006 Edwards, 2001, Presenting risk information a review of the effects of framing and other manipulations on patient outcomes, J Health Commun, 6, 61, 10.1080/10810730150501413 Blasini, 2018, The role of patient–practitioner relationships in placebo and nocebo phenomena, Int Rev Neurobiol, 139, 211, 10.1016/bs.irn.2018.07.033 Howick, 2013, Are treatments more effective than placebos? A systematic review and meta-analysis, PLoS One, 8, 10.1371/journal.pone.0062599 Abrams, 1998, Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder, Br J Urol, 81, 801, 10.1046/j.1464-410x.1998.00717.x Abrams, 2006, Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome, Int J Urol, 13, 692, 10.1111/j.1442-2042.2006.01387.x Cardozo, 2004, Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder, J Urol, 172, 1919, 10.1097/01.ju.0000140729.07840.16 Cardozo, 2008, Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial, BJU Int, 102, 1120, 10.1111/j.1464-410X.2008.07939.x Chapple, 2004, Randomized, double‐blind placebo‐and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder, BJU Int, 93, 303, 10.1111/j.1464-410X.2004.04606.x Chapple, 2007, Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg, Eur Urol, 52, 1195, 10.1016/j.eururo.2007.05.027 Chapple, 2007, Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial, Curr Med Res Opin, 23, 2347, 10.1185/03007X226294 Chapple, 2014, Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double‐blind, placebo‐controlled EIGHT trial, BJU Int, 114, 418, 10.1111/bju.12678 Chu, 2009, Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder, Curr Ther Res, 70, 405, 10.1016/j.curtheres.2009.11.001 Chua, 2018, Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment, Low Urin Tract Symptoms, 10, 135, 10.1111/luts.12152 Dmochowski, 2007, Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder, Eur Urol, 51, 1054, 10.1016/j.eururo.2006.10.005 Dmochowski, 2008, Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study, Urology, 71, 449, 10.1016/j.urology.2007.11.008 Dmochowski, 2010, Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder, Urology, 75, 62, 10.1016/j.urology.2009.09.018 Drutz, 1999, Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder, Int Urogynecol J, 10, 283, 10.1007/s001929970003 DuBeau, 2014, Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial, J Urol, 191, 395, 10.1016/j.juro.2013.08.027 Ginsberg, 2013, Efficacy of fesoterodine compared with extended‐release tolterodine in men and women with overactive bladder, BJU Int, 112, 373, 10.1111/bju.12174 Goldfischer, 2015, Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study, Neurourol Urodyn, 34, 37, 10.1002/nau.22504 Gotoh, 2011, Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double‐blind, placebo‐controlled trial, Int J Urol, 18, 365, 10.1111/j.1442-2042.2011.02732.x Haab, 2004, Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder, Eur Urol, 45, 420, 10.1016/j.eururo.2004.01.008 Hajebrahimi, 2014, Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial, Int J Urol, 21, A146 Herschorn, 2008, Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms, Curr Med Res Opin, 24, 3513, 10.1185/03007990802537122 Herschorn, 2010, Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial, BJU Int, 105, 58, 10.1111/j.1464-410X.2009.09086.x Herschorn, 2017, Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study), BJU Int, 120, 562, 10.1111/bju.13882 Homma, 2003, Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial, BJU Int, 92, 741, 10.1046/j.1464-410X.2003.04468.x Kaplan, 2011, Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial, BJU Int, 107, 1432, 10.1111/j.1464-410X.2010.09640.x Kaplan, 2014, Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER, Int J Clin Pract, 68, 1065, 10.1111/ijcp.12464 Kosilov, 2014, Effectiveness of combined high–dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy, Cent Eur J Urol, 67, 43 Kosilov, 2015, The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection, Arab J Urol, 13, 203, 10.1016/j.aju.2015.07.003 Kosilov, 2015, A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron, Arch Gerontol Geriatr, 61, 212, 10.1016/j.archger.2015.06.006 Kuo, 2015, Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials, Urol Sci, 26, 41, 10.1016/j.urols.2014.12.010 Kuo, 2015, Results of a randomized, double‐blind, parallel‐group, placebo‐and active-controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia, Neurourol Urodyn, 34, 685, 10.1002/nau.22645 Lipton, 2005, Assessment of cognitive function of the elderly population: effects of darifenacin, J Urol, 173, 493, 10.1097/01.ju.0000148963.21096.5d Malone‐Lee, 2001, The Tolterodine in the Elderly Study Group. Tolterodine: a safe and effective treatment for older patients with overactive bladder, J Am Geriatr Soc, 49, 700, 10.1046/j.1532-5415.2001.49144.x Marencak, 2011, Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder, Neurourol Urodyn, 30, 75, 10.1002/nau.20928 Mitcheson, 2019, Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial, Eur Urol, 75, 274, 10.1016/j.eururo.2018.10.006 Nitti, 2006, Efficacy and tolerability of tolterodine extended‐release in continent patients with overactive bladder and nocturia, BJU Int, 97, 1262, 10.1111/j.1464-410X.2006.06146.x Nitti, 2013, Results of a randomized phase III trial of mirabegron in patients with overactive bladder, J Urol, 189, 1388, 10.1016/j.juro.2012.10.017 Orri, 2014, Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial, Contemp Clin Trials, 38, 190, 10.1016/j.cct.2014.04.009 Robinson, 2016, Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled shrink study, Neurourol Urodyn, 35, 819, 10.1002/nau.22808 Sand, 2009, Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome, Int Urogynecol J, 20, 1431, 10.1007/s00192-009-0969-8 Sand, 2012, Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome, Am J Obstet Gynecol, 206, 10.1016/j.ajog.2011.08.005 Song, 2015, The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double‐blind, placebo‐controlled phase 2 study, Int J Clin Pract, 69, 242, 10.1111/ijcp.12540 Staskin, 2007, Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial, J Urol, 178, 978, 10.1016/j.juro.2007.05.058 Staskin, 2009, Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study, J Urol, 181, 1764, 10.1016/j.juro.2008.11.125 Toglia, 2009, Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial, Postgrad Med, 121, 151, 10.3810/pgm.2009.09.2062 Van Kerrebroeck, 2001, Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder, Urology, 57, 414, 10.1016/S0090-4295(00)01113-4 Vardy, 2009, Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient‐reported outcomes: results from VIBRANT–a double‐blind, placebo‐controlled trial, Int J Clin Pract, 63, 1702, 10.1111/j.1742-1241.2009.02209.x Wagg, 2020, Efficacy, safety, and tolerability of mirabegron in patients aged ≥ 65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR), Eur Urol, 77, 211, 10.1016/j.eururo.2019.10.002 Weiss, 2013, Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency, J Urol, 189, 1396, 10.1016/j.juro.2012.11.067 Yamaguchi, 2007, Randomized, double‐blind, placebo‐and propiverine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder, BJU Int, 100, 579, 10.1111/j.1464-410X.2007.07031.x Yamaguchi, 2014, Efficacy and safety of once‐daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double‐blind trial, Int J Urol, 21, 586, 10.1111/iju.12372 Yamaguchi, 2014, Phase III, randomised, double‐blind, placebo‐controlled study of the β3‐adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder, BJU Int, 113, 951, 10.1111/bju.12649 Yamaguchi, 2016, Optimum dose of once‐daily oxybutynin patch in Japanese patients with overactive bladder: a randomized double‐blind trial versus placebo, Low Urin Tract Symptoms, 8, 150, 10.1111/luts.12088 Yamaguchi, 2015, Efficacy and safety of the selective β3‐adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study, Low Urin Tract Symptoms, 7, 84, 10.1111/luts.12053 Yoshida, 2018, Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study, Eur Urol, 73, 783, 10.1016/j.eururo.2017.12.022 Zinner, 2004, Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial, J Urol, 171, 2311, 10.1097/01.ju.0000127742.73136.0c